Agon Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 1.70 M
- Company Age 31 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
- Revenue Growth -21.51%
- Profit Growth -29.84%
- Ebitda -29.13%
- Net Worth 23.41%
- Total Assets 42.27%
About Agon Pharma
Agon Pharma Pvt Ltd (APPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 16 December 1993 and has a history of 31 years and two months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.70 M.
The company currently has active open charges totaling ₹3.00 M.
Tanaji Patil and Sampatrao Patil serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231MH1993PTC075625
- Company No.
075625
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does Agon Pharma Pvt Ltd offer?
Agon Pharma Pvt Ltd offers a wide range of products and services, including Psoriasis Ointment, Dithranol Ointment.
Who are the key members and board of directors at Agon Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tanaji Patil  | Director | 16-Dec-1993 | Current |
| Sampatrao Patil | Director | 01-Apr-2003 | Current |
Financial Performance of Agon Pharma.
Agon Pharma Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.51% decrease. The company also saw a substantial fall in profitability, with a 29.84% decrease in profit. The company's net worth Soared by an impressive increase of 23.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agon Pharma?
In 2021, Agon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Jul 2004 | Bank Of India | ₹3.00 M | Open |
How Many Employees Work at Agon Pharma?
Agon Pharma has a workforce of 11 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
